Human anti-CD27 antibodies, methods and uses

US9102737B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• John Chen · San Diego, US
• Johan Fransson · San Diego, US
• Natalie Fursov · Spring House, US
• Damon Hamel · San Diego, US
• Thomas Malia · Philadelphia, US
• Galina Obmolova · Phoenixville, US
• Tatiana Ort · Spring House, US
• Michael Rycyzyn · Berwyn, US
• Michael Scully · Spring House, US
• Raymond Sweet · Via Enrico Fermi, US
• Alexey Teplyakov · Spring House, US
• John Wheeler · Spring House, US
• Juan Carlos Almagro · Brookline, US

Key dates

• Filing date: Mar 15, 2013
• Grant date: Aug 11, 2015
• Expiry date: Aug 1, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.